Sector News

Germany's Merck explores sale of biosimilar drug business -sources

October 31, 2016
Life sciences

German chemicals and pharmaceuticals company Merck KGaA is exploring a sale of its biosimilars unit, according to people familiar with the matter, as that business faces fierce competition from larger players in the sector.

Biosimilars, the biotechnology-based equivalents of generic drugs, have become increasingly popular amid a drive to curb price increases. Stefan Oschmann, however, who took over as Merck’s CEO earlier this year, has been focused on finding ways to safeguard his company’s leading position in the multiple sclerosis market. Its top selling drug in this space is Rebif.

Merck has hired investment bank JPMorgan Chase & Co to sound out potential buyers for the biosimilar business, the people said on Friday. There is no guarantee that the discussions will result in any deal, they added.

Merck’s biosimilars business could be worth as much as $1 billion because of its long-term sales potential, the people said.

The sources asked not to be identified because the deliberations are confidential. Merck, which is independent of U.S. drug marker Merck & Co Inc, declined to comment. A JPMorgan spokeswoman offered no immediate comment.

Merck’s biosimilar business includes a drug in advanced clinical trials that is a competitor to AbbVie Inc’s popular arthritis treatment Humira. The unit also has several early-stage compounds.

Merck is facing off against several larger competitors, including Pfizer Inc and Novartis AG, both of which have won regulatory approval for biosimilar drugs.

Biosimilars have become an increasing area of focus for investors and industry executives in the past year, as regulators have begun approving a handful of compounds in the United States.

Biosimilars are more complex than traditional drugs, requiring genetically engineered proteins. The U.S. Food and Drug Administration was not allowed to consider generic versions of biologic drugs until U.S. President Barack Obama’s Affordable Care Act was enacted in 2010.

So far, the FDA has approved four biosimilar drugs, most recently a competitor for Humira made by Amgen Inc. There are more than 60 biosimilars awaiting approval.

More of those drugs are expected to be approved in the coming years, as biologic drugs representing more than $30 billion in sales will lose their patent protection between now and 2020, according to data from IMS Health.

In Europe, where biosimilars were approved by regulators as early as 2006, more than 21 biosimilars made by 14 companies have been approved.

By Carl O’Donnell and Greg Roumeliotis

Source: Reuters via Daily Mail

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.